BSLN — Basilea Pharmaceutica AG Allschwil Balance Sheet
0.000.00%
Last trade - 00:00- CH₣484.66m
- CH₣535.63m
- CH₣157.63m
- 42
- 18
- 46
- 25
Annual balance sheet for Basilea Pharmaceutica AG Allschwil, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 129 | 162 | 149 | 84.7 | 59.9 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 28.3 | 32.4 | 64.4 | 61.7 | 58.1 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 185 | 224 | 241 | 175 | 152 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 5.16 | 5.28 | 2.92 | 21.6 | 20.6 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 221 | 230 | 247 | 221 | 173 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 75.5 | 50.2 | 174 | 74.8 | 47.6 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 314 | 332 | 306 | 242 | 183 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | -93 | -102 | -58.6 | -20.7 | -10 |
| Total Liabilities & Shareholders' Equity | 221 | 230 | 247 | 221 | 173 |
| Total Common Shares Outstanding |